[1] |
Husson RN, James BE, Young RA. Gene replacement and expression of foreign DNA in mycobacteria. J Bacteriol, 1990, 172(2): 519-524. doi:10.1128/jb.172.2.519-524.1990.
doi: 10.1128/jb.172.2.519-524.1990
pmid: 2153655
|
[2] |
Parish T, Stoker NG. Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiology (Reading), 2000, 146 (Pt 8): 1969-1975. doi:10.1099/00221287-146-8-1969.
doi: 10.1099/00221287-146-8-1969
URL
|
[3] |
Bardarov S, Bardarov S, Pavelka MS, et al. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M.bovis BCG and M.smegmatis. Microbiology (Reading), 2002, 148(Pt 10): 3007-3017. doi:10.1099/00221287-148-10-3007.
doi: 10.1099/00221287-148-10-3007
URL
|
[4] |
Brouns SJ, Jore MM, Lundgren M, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science, 2008, 321(5891): 960-964. doi:10.1126/science.1159689.
doi: 10.1126/science.1159689
pmid: 18703739
|
[5] |
Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 2012, 337(6096): 816-821. doi:10.1126/science.1225829.
doi: 10.1126/science.1225829
pmid: 22745249
|
[6] |
Chhotaray C, Tan Y, Mugweru J, et al. Advances in the development of molecular genetic tools for Mycobacterium tuberculosis. J Genet Genomics, 2018: S1673-8527(18)30114-0. doi:10.1016/j.jgg.2018.06.003.
doi: 10.1016/j.jgg.2018.06.003
|
[7] |
van Kessel JC, Hatfull GF. Recombineering in Mycobacterium tuberculosis. Nat Methods, 2007, 4(2): 147-152. doi:10.1038/nmeth996.
doi: 10.1038/nmeth996
pmid: 17179933
|
[8] |
Yan MY, Yan HQ, Ren GX, et al. CRISPR-Cas12a-Assisted Recombineering in Bacteria. Appl Environ Microbiol, 2017, 83(17): e00947-17. doi:10.1128/AEM.00947-17.
doi: 10.1128/AEM.00947-17
|
[9] |
Shuman S, Glickman MS. Bacterial DNA repair by non-homologous end joining. Nat Rev Microbiol, 2007, 5(11): 852-861. doi:10.1038/nrmicro1768.
doi: 10.1038/nrmicro1768
pmid: 17938628
|
[10] |
Selle K, Barrangou R. Harnessing CRISPR-Cas systems for bacterial genome editing. Trends Microbiol, 2015, 23(4): 225-232. doi:10.1016/j.tim.2015.01.008.
doi: 10.1016/j.tim.2015.01.008
pmid: 25698413
|
[11] |
Sun B, Yang J, Yang S, et al. A CRISPR-Cpf1-Assisted Non-Homologous End Joining Genome Editing System of Mycobacterium smegmatis. Biotechnol J, 2018, 13(9): e1700588. doi:10.1002/biot.201700588.
doi: 10.1002/biot.201700588
|
[12] |
Yan MY, Li SS, Ding XY, et al. A CRISPR-Assisted Nonhomologous End-Joining Strategy for Efficient Genome Editing in Mycobacterium tuberculosis. mBio, 2020, 11(1): e02364-19. doi:10.1128/mBio.02364-19.
doi: 10.1128/mBio.02364-19
|
[13] |
Stephanou NC, Gao F, Bongiorno P, et al. Mycobacterial nonhomologous end joining mediates mutagenic repair of chromosomal double-strand DNA breaks. J Bacteriol, 2007, 189(14): 5237-5246. doi:10.1128/JB.00332-07.
doi: 10.1128/JB.00332-07
pmid: 17496093
|
[14] |
Komor AC, Kim YB, Packer MS, et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 2016, 533(7603): 420-424. doi:10.1038/nature17946.
doi: 10.1038/nature17946
URL
|
[15] |
Gaudelli NM, Komor AC, Rees HA, et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature, 2017, 551(7681): 464-471. doi:10.1038/nature24644.
doi: 10.1038/nature24644
URL
|
[16] |
Komor AC, Zhao KT, Packer MS, et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. Sci Adv, 2017, 3(8): eaao4774. doi:10.1126/sciadv.aao4774.
doi: 10.1126/sciadv.aao4774
URL
|
[17] |
Ding XY, Li SS, Geng YM, et al. Programmable Base Editing in Mycobacterium tuberculosis Using an Engineered CRISPR RNA-Guided Cytidine Deaminase. Front Genome Ed, 2021, 3: 734436. doi:10.3389/fgeed.2021.734436.
doi: 10.3389/fgeed.2021.734436
URL
|
[18] |
Qi LS, Larson MH, Gilbert LA, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell, 2021, 184(3): 844. doi:10.1016/j.cell.2021.01.019.
doi: 10.1016/j.cell.2021.01.019
pmid: 33545038
|
[19] |
Bosch B, DeJesus MA, Poulton NC, et al. Genome-wide gene expression tuning reveals diverse vulnerabilities of M.tuberculosis. Cell, 2021, 184(17): 4579-4592.e24. doi:10.1016/j.cell.2021.06.033.
doi: 10.1016/j.cell.2021.06.033
URL
|
[20] |
Choudhary E, Thakur P, Pareek M, et al. Gene silencing by CRISPR interference in mycobacteria. Nat Commun, 2015, 6: 6267. doi:10.1038/ncomms7267.
doi: 10.1038/ncomms7267
pmid: 25711368
|
[21] |
Singh AK, Carette X, Potluri LP, et al. Investigating essential gene function in Mycobacterium tuberculosis using an efficient CRISPR interference system. Nucleic Acids Res, 2016, 44(18): e143. doi:10.1093/nar/gkw625.
doi: 10.1093/nar/gkw625
URL
|
[22] |
Rock JM, Hopkins FF, Chavez A, et al. Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform. Nat Microbiol, 2017, 2: 16274. doi:10.1038/nmicrobiol.2016.274.
doi: 10.1038/nmicrobiol.2016.274
pmid: 28165460
|
[23] |
McNeil MB, Ryburn HW, Tirados J, et al. Multiplexed transcriptional repression identifies a network of bactericidal interactions between mycobacterial respiratory complexes. iScience, 2021, 25(1): 103573. doi:10.1016/j.isci.2021.103573.
doi: 10.1016/j.isci.2021.103573
URL
|
[24] |
Adolph C, McNeil MB, Cook GM. Impaired Succinate Oxidation Prevents Growth and Influences Drug Susceptibility in Mycobacterium tuberculosis. mBio, 2022, 13(4): e0167222. doi:10.1128/mbio.01672-22.
doi: 10.1128/mbio.01672-22
URL
|
[25] |
Xiao J, Jia H, Pan L, et al. Application of the CRISPRi system to repress sepF expression in Mycobacterium smegmatis. Infect Genet Evol, 2019, 72: 183-190. doi:10.1016/j.meegid.2018.06.033.
doi: S1567-1348(18)30469-6
pmid: 31242975
|
[26] |
Babunovic GH, DeJesus MA, Bosch B, et al. CRISPR Interference Reveals That All-Trans-Retinoic Agcid Promotes Macrophage Control of Mycobacterium tuberculosis by Limiting Bacterial Access to Cholesterol and Propionyl Coenzyme A. mBio, 2022, 13(1): e0368321. doi:10.1128/mbio.03683-21.
doi: 10.1128/mbio.03683-21
URL
|
[27] |
McNeil MB, Cook GM. Utilization of CRISPR Interference To Validate MmpL3 as a Drug Target in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2019, 63(8): e00629-19. doi:10.1128/AAC.00629-19.
doi: 10.1128/AAC.00629-19
|
[28] |
Li S, Poulton NC, Chang JS, et al. CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis. Nat Microbiol, 2022, 7(6): 766-779. doi:10.1038/s41564-022-01130-y.
doi: 10.1038/s41564-022-01130-y
URL
|
[29] |
Poulton NC, Azadian ZA, DeJesus MA, et al. Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE 1 Inhibitors in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2022, 66(9): e0090422. doi:10.1128/aac.00904-22.
doi: 10.1128/aac.00904-22
|
[30] |
Yan MY, Zheng D, Li SS, et al. Application of combined CRISPR screening for genetic and chemical-genetic interaction profiling in Mycobacterium tuberculosis. Sci Adv, 2022, 8(47): eadd5907. doi:10.1126/sciadv.add5907.
doi: 10.1126/sciadv.add5907
URL
|